Ieq Capital LLC Makes New $2.36 Million Investment in Thermo Fisher Scientific Inc. $TMO

Key Points

• Ieq Capital acquired 4,707 Thermo Fisher Scientific shares in the second quarter, worth approximately $2.36 million. Institutional investors and hedge funds own 89.23% of the company.
• Thermo Fisher reported quarterly EPS of $6.03 and revenue of $11.99 billion, beating analyst estimates; revenue increased 10.5% year over year. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $619.41.
• TMO shares opened at $627.96, near their 52-week high of $647.00. The company declared a quarterly dividend of $0.47, while insiders have sold approximately $43.95 million of stock over the past three months.

Ieq Capital LLC acquired a new stake in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 4,707 shares of the medical research company's stock, valued at approximately $2,360,000.

Several other large investors have also recently bought and sold shares of the stock. Legacy Wealth Managment LLC ID raised its position in shares of Thermo Fisher Scientific by 78.6% during the first quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock valued at $25,000 after buying an additional 22 shares during the last quarter. Kilter Group LLC bought a new position in Thermo Fisher Scientific during the second quarter valued at about $25,000. Allied Private Wealth LLC acquired a new position in Thermo Fisher Scientific in the 2nd quarter valued at approximately $26,000. High Note Wealth LLC lifted its position in shares of Thermo Fisher Scientific by 170.6% in the 4th quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after acquiring an additional 29 shares during the period. Finally, Swiss RE Ltd. acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $28,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Down 0.1%

Shares of NYSE:TMO opened at $627.96 on Wednesday. The company has a market capitalization of $232.19 billion, a PE ratio of 33.78, a P/E/G ratio of 2.56 and a beta of 0.85. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.18 and a current ratio of 1.55. The company's fifty day moving average is $548.75 and its 200-day moving average is $510.05. Thermo Fisher Scientific Inc. has a 52 week low of $435.27 and a 52 week high of $647.00.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. Thermo Fisher Scientific had a net margin of 15.04% and a return on equity of 17.09%. The firm's quarterly revenue was up 10.5% on a year-over-year basis. During the same period last year, the firm posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be issued a $0.47 dividend. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's payout ratio is presently 10.11%.

Analyst Ratings Changes

TMO has been the subject of several research reports. HSBC cut Thermo Fisher Scientific from a "buy" rating to a "hold" rating and reduced their target price for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Weiss Ratings raised shares of Thermo Fisher Scientific from a "hold (c-)" rating to a "hold (c)" rating in a report on Tuesday, July 14th. Morgan Stanley lifted their target price on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. Sanford C. Bernstein started coverage on shares of Thermo Fisher Scientific in a research report on Friday, June 26th. They issued a "market perform" rating and a $520.00 price target for the company. Finally, KeyCorp reaffirmed an "overweight" rating on shares of Thermo Fisher Scientific in a report on Tuesday, May 26th. One analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have given a Hold rating to the company's stock. According to data from MarketBeat, Thermo Fisher Scientific has an average rating of "Moderate Buy" and an average price target of $619.41.

Insider Activity

In related news, CEO Marc N. Casper sold 10,000 shares of Thermo Fisher Scientific stock in a transaction dated Thursday, August 20th. The stock was sold at an average price of $629.27, for a total value of $6,292,700.00. Following the completion of the transaction, the chief executive officer directly owned 123,925 shares of the company's stock, valued at $77,982,284.75. The trade was a 7.47% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael D. Shafer sold 25,500 shares of the company's stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the transaction, the executive vice president owned 20,994 shares in the company, valued at approximately $12,596,400. This trade represents a 54.85% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 73,493 shares of company stock worth $43,950,381. 0.33% of the stock is currently owned by insiders.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source